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cords were reviewed from 2007 to 2009 to extract patients with principle diagnosis
of ICD-9 codes for cellulitis, abscess, postoperative and traumatic wound infec-
tions, and other conditions related to ABSSSI. We assessed inpatient utilization in
terms of LOS and ICU time, and inpatient costs stratified by initial antibiotic treat-
ment. We also assessed the frequency of in-hospital mortality and empiric treat-
ment failure. RESULTS: Inpatient treatment of ABSSSI increased by 15.4% from
2007 to 2009. In 2009, 110,457 ABSSSI patients were admitted to Premier hospitals,
with 65% admitted through the ER. The initial antibiotic treatment was vancomy-
cin (49.9%) and clindamycin (15.9%). The average LOS was 5.3 days. The average
cost per stay was $8000. The most costly departmental charges were room/board
($1000) and pharmacy ($650). 17.2% of patients failed on initial antibiotic treatment,
resulting in additional LOS of 5 days and $6000 per stay on average. With approx.
750K admissions for ABSSSI in the United States, this extrapolates to a US hospital
economic burden of $6 billion/yr. CONCLUSIONS: The economic burden of hos-
pitalization for ABSSSI in the United States is significant. Antibiotic treatments
offering the possibility of treating a greater proportion of patients currently hospi-
talized in an ambulatory or observational setting by avoiding or shortening hospi-
tal stays may significantly reduce the cost to the US health care system.
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OBJECTIVES: Congenital cytomegalovirus (CMV) infection during pregnancy are a
serious, yet not well recognized health problem. The aim of our study is to assess
the annual cost of diagnosis and prevention of congenital cytomegalovirus infec-
tion by Cytotect in Hungary.METHODS:We built a model on estimating the costs.
Data on deliveries derived from the database of the Hungarian Central Statistical
Office. Cost items were calculated according to the standard reimbursement list of
the Hungarian National Health Insurance Fund, the only health care financing
agency in Hungary. The number of livebirths was 90,335 in 2010 in Hungary. The
cost of CMV Ig-test was 2 Euro. Average bodyweight was 80 kg, the average dosis of
Cytotec was 8000 unit or 80 ml per patient with a cost of 8 Euro per ml. CMV-
seronegative women (40 % of all deliveries) are the high risk group applying 4 tests
during pregnancy. Seroconversion rate was 1 %. RESULTS: For all pregnant women
(N90335), the total annual cost of diagnosis of congenital cytomegalovirus infec-
tion was calculated 180,670 Euro (or 54.2 million Hungarian Forint). For CMV-sero-
negative high risk women (N36134) the total annual cost of diagnosis was as-
sessed 289072 Euro (or 86.7 million Hungarian Forint). The cost of prevention of all
women with primary infection during pregnancy was 2.89 million Euro (or 867.2
million Hungarian Forint). CONCLUSIONS: Both the diagnosis and prevention of
congenital cytomegalovirus (CMV) infection during pregnancy represents a reason-
able cost in Hungary. Further study should focus on the effectiveness of preven-
tion.
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OBJECTIVES: The use of combined tetanus toxoid, reduced diphtheria toxoid, and
acellular pertussis vaccine (Tdap) in pregnant and postpartum women provides
personal protection and may reduce the risk of transmission of pertussis to their
young infants. The study seeks to assess the economic benefits associated with a
hospital-based postpartum Tdap vaccination strategy. METHODS: A decision tree
model was constructed to calculate the potential cost-benefit of this strategy from
a health care system or societal perspective. Probabilities and costs were derived
from published literature, Centers for Disease Control and Prevention data, and
expert recommendations. The maternal vaccination protection period for infants
was defined as 7 months, as the infants do not receive a full series of pertussis
immunization before 6 months of age, with 1 month added for maximal develop-
ment of immunity. 10-year vaccine protection for birth mothers was estimated in
the model. All cost estimates were inflated to year 2010 US dollars and discounted
at a 3% annual discount rate. RESULTS: From a societal perspective, the average
costs per vaccinated and unvaccinated mother were estimated at $132.92 and
$232.75, respectively. Our model suggests an expected net benefit (ENB) of $99.83
per postpartum vaccinated mother. The overall societal benefits in the cohort of
U.S. birth mothers ranged from $89.8  $287.5 million, depending on the vaccine
coverage rate. If including direct medical costs only, the ENB was estimated at
-$27.26 per vaccinatedmother, suggesting that this strategy is not cost-saving from
a health care system perspective. Annual incidence in birth mothers and Tdap
efficacy exhibited substantial impact on the model from one-way and two-way
sensitivity analyses. CONCLUSIONS: Postpartum Tdap vaccination is likely to gen-
erate net benefits in the base case from a societal perspective, if the annual inci-
dence of pertussis among birth mothers exceeds 140 cases per 100,000.
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BACKGROUND: In US treatment guidelines, efavirenz (EFV) is the preferred non-
nucleoside reverse transcriptase inhibitor (NNRTI) for first-line treatment of HIV. In
the ECHO and THRIVE trials comparing EFV with another NNRTI, rilpivirine (RPV),
both medications had similar rates of virologic suppression at 96-weeks; however,
RPV had higher rates of virologic failure and drug resistance and lower rates of
discontinuation due to adverse events. OBJECTIVES: To estimate the cost-effec-
tiveness of EFV versus RPV in first-line HIV treatment in the US. METHODS: A
Markovmodel with 14 health states was constructed to estimate 10-year costs and
clinical outcomes from a US payer perspective for antiretroviral naïve HIV patients
initiating EFV or RPV. First-line efficacy data came from 96-week results of the
ECHO and THRIVE trials, which compared EFV and RPV, both in combination with
two nucleos(t)ide reverse transcriptase inhibitors. Other clinical inputs, mortality
rates and costs (2011 US$) came from published sources. Subsequent therapy lines
(second, third, non-suppressive) were based on US treatment guidelines and com-
mon to both treatment arms. Robustness of study results was assessed in sensi-
tivity analyses that varied model inputs by 25%. RESULTS: In the base case, total
costs over 10 years were lower for EFV versus RPV ($214,031 versus $222,090). Life
expectancy (8.44 years) and life years without AIDS (8.40 years) were the same and
life years in virologic suppression were similar (EFV 7.87 years, RPV7.86 years).
EFV was modestly cost-saving versus RPV in terms of incremental cost-effective-
ness per life-year gained, per life-year gained in viral suppression, and per life-year
gainedwithout AIDS. In sensitivity analyses, EFV remained cost-saving versus RPV
more than 90% of the time, demonstrating the robustness of study results.
CONCLUSIONS: Over a 10-year time horizon, EFV was predicted to be modestly
cost-saving compared with RPV in HIV patients initiating first-line treatment in
the US.
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OBJECTIVES: To evaluate the comparative cost-effectiveness of sequential i.v./p.o.
CAP treatment with moxifloxacin versus amoxicillin/clavulanic acid (AMCLA),
ceftriaxone amoxicillin/clavulanic (CEFAMCLA) acid and cefotaxime macro-
lides (COMB) in adult patients. METHODS: Patients were randomized in four
groups. MOX group received moxifloxacin 400 mg i.v. once-daily with further
switch to p.o. formulation 400 mg daily. AMCLA group received amoxicillin/clavu-
lanic acid 1200 mg i.v. once-daily with further switch to p.o. formulation 1000 mg
twice-daily. CEFAMCLA group received ceftriaxone 1000 mg i.v. once-daily with
further switch to amoxicillin/clavulanic acid 1000 mg p.o. twice daily. COMB group
received either cefotaxime 1000 mg i.m. 3 times per day as monotherapy or in
combination with oral azithromycin or clarithromycin. Efficacy and safety criteria
were evaluated according to clinical data, laboratory tests and X-ray examination.
Cost-effectiveness analysis was performed. RESULTS: MOX group included 30 pa-
tients, mean age 33.616.5 years; AMCLA group included 30 patients, mean age
27,115,4 years; CEF/AMCLA group included 47 patients, mean age 23,59,6 years;
COMB group included 50 patients, mean age 26.515.6 years. The efficacy of treat-
ment and in-hospital stay duration were: 96.7% and 15.12.1 days in MOX group,
93.3% and 17,02,7 days in AMCLA group, 95.7% and 16,43,4 days in CEF/AMCLA
group, 88.0% and 18.23.7 days in COMB group. Direct medical costs including
antibacterial treatment and in-hospital days were $1536 in MOX, $1540 in AMCLA,
$1502 in CEF/AMCLA and $1671 in COMB group. CERMOX 1589$, CERAMCLA1650$,
CERCEF/AMCLA1570$, CERCOMB 1899$. CONCLUSIONS: Sequential CAP treatment
with moxifloxacin compared to other alternatives in adult patients is the most
effective, convenient and compliant therapy. In terms of cost-effectiveness, it
dominants over AMCLA and COMB treatment and have the comparable costs with
CEFAMCLA group.
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OBJECTIVES: Telaprevir is a new direct acting antiviral for the treatment of geno-
type 1 hepatitis C virus (HCV) infection. This analysis evaluated the cost-effective-
ness of TVR/PR therapy compared to PR alone in treatment-naïve and previously
treated G1 chronic HCV patients. Cost-effectiveness is considered in terms of in-
cremental cost per quality-adjusted life-year (QALY) gained from the perspective of
the NHS in Scotland. METHODS: Two Markov models were developed to evaluate
treatments studied in TVR phase III clinical trials: TVR response-guided therapy of
12weeks of TVRwith PR [24weeks PR for patients achieving an extended rapid viral
response (eRVR), 48 weeks of PR for patients not achieving an eRVR] for treatment-
naïve patients; 12 weeks of TVR in combination with 48 weeks of PR therapy for
treatment-experienced patients. SVR rates of 75% and 44% for TVR/PR and PR alone
respectively are taken from the TVR12/PR and PBO/PR treatment arms in the AD-
VANCE trial. SVR rates of 83%, 59% and 29% for TVR/PR and 24%, 15% and 5% for PR
alone in prior relapse, prior partial response and prior null response patients, re-
spectively are taken from the TVR12/PR and PBO/PR treatment arms in the REALIZE
trial. RESULTS: The analysis shows higher costs and improved outcomes associ-
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atedwith TVR/PR relative to PR alone, resulting in an ICER of £14,230 for treatment-
naïve patients and £9,440 across the overall treatment-experienced patients. The
ICER of the prior relapse, prior partial responder and prior null-responder sub-
populations, were £5,363, £10,558 and £27,725, respectively. CONCLUSIONS: The
introduction of telaprevir to current standard of care for HCV genotype 1 patients is
clinically more efficacious than PR alone and cost-effective for both treatment
naïve and experienced patients at the £20,000 and £30,000 willingness-to-pay
thresholds.
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OBJECTIVES: Streptococcus pneumoniae causes significant morbidity and mortality
worldwide in both children and adults. The aim of this analysis is to evaluate the
cost-effectiveness of vaccinating the Colombia population over 50 years with 13-
valent pneumococcal conjugated vaccine (PCV 13) vs. 23-valent pneumococcal
polysaccharide vaccine (PPSV23) to estimate the clinical benefits and associated
costs from the third-party payer perspective in Colombia. METHODS: A Markov
model simulating vaccination and outcomes was adapted to Colombian settings,
using a timehorizon of 5 years (5% annual discount rate). Comparatorswere PCV13,
PPSV23 (70% coverage) and no vaccination; revaccinationwith PPSV23 after 5 years
in adults at high risk according to CDC criteria was considered. Probabilities and
costs were extracted from a literature review, the incidence of diseases was re-
trieved from local database and costs are presented in 2011 US$. Effectiveness
measures were the number of pneumococcal diseases and deaths prevented, as
well as life years (LY) saved. Probabilistic sensitivity analyses were developed.
RESULTS:Over a 5 year period, vaccinatingwith PCV13 compared to PPSV23 and no
vaccination prevents 3,277 and 15,930 cases of invasive pneumococcal disease;
156,722 and 157,893 cases of hospitalized pneumonia; 11,383 and 12,358 non-com-
plicated pneumonia and 6,613 and 7,691 deaths respectively, PCV13 saves 13,347
LY’s compared to PPSV23 and 18,321 LY’s compared to no vaccination. Total ex-
pected savings (considering vaccination costs  medical costs and expressed in
US$ millions) for PCV13 was US$ 113.7M compared to PPSV23 and US$ 74.9M com-
pared to no vaccination (total expected costs: US$ 1,462.5M; US$ 1,576.2M and US$
1,537.4M respectively). CONCLUSIONS: Vaccinating adults over 50 years with
PCV13 in Colombia is a cost-saving alternative in comparison to PPSV23 and to no
vaccination (US$ 13 and US$9 per patient, respectively). These savings could posi-
tive impact the burden of disease and study findings could support the decision-
making process in favor of PCV13.
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OBJECTIVES: Telaprevir and Boceprevir were approved in May 2011 for the treat-
ment of chronic hepatitis C in combination with the standard therapy of peginter-
feron-ribavirin. The objective of this study was to compare the cost-effectiveness
of the addition of Telaprevir or Boceprevir to the standard therapy versus the
standard therapy alone for the treatment of previously untreated chronic hepatitis
C genotype 1 virus infection. METHODS: A Markov model was constructed using
TreeAge Pro version 2011. Six Markov states were identified based on the clinical
progression of chronic hepatitis C. The model was run over a 28 year time horizon
with 1 year cycle lengths. Clinical inputs (treatment response rates and probabili-
ties of adverse drug reactions) were obtained from two published phase III clinical
trials comparing the combination of Telaprevir or Boceprevir with the standard
therapy versus treating patients with standard therapy alone. Treatment costs,
transition probabilities, and health state utilities were obtained from the Medical
Expenditure Panel Survey data and other published literature. The primary out-
come measure used was quality adjusted life years (QALYs). Future costs and out-
comes were discounted at 5%. The analysis was conducted from the payer’s per-
spective. Multiple one-way sensitivity analyses were conducted by varying drug
costs, treatment response rates and the discount rate. RESULTS: The incremental
cost effectiveness ratio (ICER) for adding Telaprevir to the standard therapy versus
the standard therapy alone was $17,974.93/QALY gained while the ICER for adding
Boceprevir to the standard therapy versus the standard therapy alone was
$9,476.61/QALY gained. CONCLUSIONS: Based on the results, adding Boceprevir or
Telaprevir to the standard therapy was found to be cost-effective as compared to
treating patients with standard therapy alone. Furthermore, adding Boceprevir to
the standard therapy was found to be more cost-effective as compared to adding
Telaprevir.
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OBJECTIVES: Influenza can cause significant mortality, morbidity and economic
burden in a population, with vulnerable groups being disproportionally affected.
Vaccinating healthy children to produce herd effect has been proposed as a strat-
egy to protect vulnerable groups. This strategy was investigated in the Hutterite
Influenza Prevention Study, a clustered RCT comparing communities with or with-
out childhood influenza immunization programs. There will be costs associated
with vaccinating all healthy children in a community; therefore there may be a
trade-off between these costs and the benefits of avoiding influenza cases. The
study objective is to evaluate the cost-effectiveness of immunizing healthy chil-
dren to create herd immunity within entire communities. METHODS: Data from
the trial were used for effect inputs. Resource utilization was recorded during the
trial and cost data were collected from third party payer, literature and internet
sources. A two-stage bootstrap (TSB) with shrinkage correction was used to esti-
mate costs and effects (influenza cases avoided).The base case incremental cost
effectiveness ratio (ICER) and sample uncertainty around this estimate were cal-
culated from the TSB results. RESULTS: Mean costs per patient for the treatment
and control armswere $51.32 and $33.26 respectively (difference $18.06). Themean
number of influenza cases was estimated to be 0.05 for the treatment arm and 0.28
for the control arm (difference 0.23). ICER was $80.36 (dominates, $2,263.82) per
case of influenza averted. The probability of the treatment arm being cost-effective
was 90% at a willingness-to-pay of $1000 per case of influenza prevented. One way
sensitivity analysis showed results to be robust. CONCLUSIONS: Immunizing
healthy children for influenza is more costly, yet more effective than no influenza
immunization in preventing cases of influenza in the entire sample. At a cost of
$80.36 to prevent a case of influenza, immunizing healthy children to protect all
community members may be considered cost-effective.
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OBJECTIVES: Candidemia accounts for 50 to 70% of the manifestations of invasive
candidiasis (IC) and in Colombia Candida albicans is the most frequently isolated
specie in IC (43.6%). The emergence of new antifungal agents such as echinocan-
dins family therapy provides great opportunities to manage candidemia, with fa-
vorable safety profile and broad spectrum fungicide. The purpose of this study was
to evaluate the cost-effectiveness of multiple treatments for non-neutropenic crit-
ically ill patients hospitalized in an intensive care unit (ICU) with highly suspected
or confirmed IC comparing amphotericin B, anidulafungin, and caspofungin from
the third-party payer perspective in Colombia. METHODS: A decision-tree model
was developed to assess the cost-effectiveness of empiric treatments for IC, using
a time horizon of 14 weeks. Comparators were: amphotericin B (0,6mg/kg/day),
anidulafungin (100mg/day), and caspofungin (50mg/day). Effectiveness data and
adverse event rates for comparators were obtained through a Colombian meta-
analysis using the results from a systematic review. Direct medical costs were
gathered from the Colombian Tariff Manual (SOAT) and acquisition costs were
retrieved from the 2011 SISMED report from Colombia. All data were validated
through a ColombianDelphi Panel who estimated schemes for IC treatment (drugs,
hospitalization, and medical manage associated with adverse events: such as
nephrotoxicity and hypokalemia). Effectiveness was expressed through life years
gained (LYG). Incremental cost per life year gained (ICER) and sensitivity analyses
were performed to test model robustness. RESULTS: Anidulafungin showed to be
cost-saving vs. caspofungin reducing overall costs (2011 US$) by US$924.80 and
gaining additional 0.47 LYG. Likewise, anidulafungin was highly cost-effective
compared to amphotericin B (ICER $1153.67/LYG); due to rates reduction of side
effect events: anidulafungin 24.4%, caspofungin 42.1% and amprothericin B 75.2%
and its associated costs. CONCLUSIONS: In Colombia, anidulafungin is the most
cost effective option for the treatment of IC in critically ill patients hospitalized at
ICU.
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OBJECTIVES: Complicated intra-abdominal infections are a public health problem
in terms of burden of illness. The purpose of this studywas to develop an economic
model based in Mexican Institute of Social Security (IMSS) resource payments in
order to evaluate the cost-effectiveness of tigecicline /Im-Cl and tigecicline/Pi-Tz vs
Cef-Met/Im-Cl; Cef-Met/Pi-Tz; ertapenem/Im-Cl and ertapenem/Pi-Tz in the treat-
ment of adults with complicated intra-abdominal infections acquired in the
community. METHODS: In a decision-tree model all patients receive first-line
treatment in hospital floor, if they fail then receive second-line treatment in ICU
The combinations were of tigecicline (100mg/day), ceftriaxone/metronidazole (2g/
1.5g/day) and ertapenem (2g/day) with imipenem/cilastatin or piperaciclin/tazo-
bactam to evaluate the cost-effectiveness of tigecicline in the treatment of compli-
cated intra-abdominal infections. The analysis time horizon was 30 days and the
currency used was US dollars. The effectiveness measure was the percentage of
clinical success that was obtained from clinical trials published in the literature
and adjusted for bacterial resistance by conditional probabilitiesmethod. Resource
use and costs were obtained from an expert panel survey and IMSS published data,
respectively. Themodel estimated cost per patient and incremental cost-effective-
ness ratios (ICER). Costs (USD 2011) and effectiveness do not were discounted.
Probabilistic sensitivity analysis was performed using Monte Carlo simulation sec-
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